Resistance is futile: targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Oncoimmunology, 2016•Taylor & Francis
Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy.
However, these reagents are subject to particular types of resistance. Several resistance
mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block
FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated
resistance.
However, these reagents are subject to particular types of resistance. Several resistance
mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block
FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated
resistance.
Abstract
Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
Taylor & Francis Online